Literature DB >> 11531946

Identification of ricin A-chain HLA class II-restricted epitopes by human T-cell clones.

M Tommasi1, D Castelletti, M Pasti, G Fracasso, I Lorenzetti, S Sartoris, C Pera, G B Ferrara, G Tridente, M Colombatti.   

Abstract

The identification of ricin toxin A-chain (RTA) epitopes and the molecular context in which they are recognized will allow strategies to be devised that prevent/suppress an anti-RTA immune response in patients treated with RTA-based immunotoxins. RTA-specific human T-cell lines and T-cell clones were produced by in vitro priming of PBMC. The T-cell clones used a limited set of Vbeta chains (Vbeta1, Vbeta2 and Vbeta8) to recognize RTA epitopes. The use of RTA deletion mutants demonstrated that T-cell lines and T-cell clones from three out of four donors responded to RTA epitopes within the domain D124-Q223, whereas one donor recognized the region I1-D124. The response to RTA peptides of T-cell lines and T-cell clones from two donors allowed the identification of immunogenic segments (D124-G140 and L161-T190) recognized in the context of different HLA-DRB1 alleles (HLA-DRB1*0801, and HLA-DRB1*11011 and B1*03011, respectively). The response to L161-T190 was investigated in greater detail. We found that the HLA-DRB1*03011 allele presents a minimal epitope represented by the sequence I175-Y183 of RTA, whereas the HLA-DRB1*11011 allele presents the minimal epitope M174-I184. RTA peptides and an I175A RTA point mutant allowed us to identify I175 as a crucial residue for the epitope(s) recognized by the two HLA-DRB1 alleles. Failure of T-cell clones to recognize ribosome inactivating proteins (RIPs) showing sequences similar but not identical to RTA further confirmed the role of I175 as a key residue for the epitope recognized in the context of HLA-DRB1*11011/03011 alleles.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11531946      PMCID: PMC1906154          DOI: 10.1046/j.1365-2249.2001.01525.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  51 in total

Review 1.  Mechanisms of central and peripheral T-cell tolerance: lessons from experimental models of multiple sclerosis.

Authors:  S Anderton; C Burkhart; B Metzler; D Wraith
Journal:  Immunol Rev       Date:  1999-06       Impact factor: 12.988

2.  IMGT/HLA database--a sequence database for the human major histocompatibility complex.

Authors:  J Robinson; A Malik; P Parham; J G Bodmer; S G Marsh
Journal:  Tissue Antigens       Date:  2000-03

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

Review 4.  Ribosome-inactivating proteins up to date.

Authors:  F Stirpe; L Barbieri
Journal:  FEBS Lett       Date:  1986-01-20       Impact factor: 4.124

5.  Limiting dilution assays for the determination of immunocompetent cell frequencies. I. Data analysis.

Authors:  C Taswell
Journal:  J Immunol       Date:  1981-04       Impact factor: 5.422

6.  Human interleukin-2 promotes proliferation of activated B cells via surface receptors similar to those of activated T cells.

Authors:  M C Mingari; F Gerosa; G Carra; R S Accolla; A Moretta; R H Zubler; T A Waldmann; L Moretta
Journal:  Nature       Date:  1984 Dec 13-19       Impact factor: 49.962

7.  Antibody formation against the cytotoxic proteins abrin and ricin in humans and mice.

Authors:  A Godal; O Fodstad; A Pihl
Journal:  Int J Cancer       Date:  1983-10-15       Impact factor: 7.396

8.  Prevention of growth of leukemia cells in mice by monoclonal antibodies directed against Thy 1.1 antigen disulfide linked to two ribosomal inhibitors:pokeweed antiviral protein or ricin A chain.

Authors:  S Ramakrishnan; L L Houston
Journal:  Cancer Res       Date:  1984-04       Impact factor: 12.701

9.  Toxicity and immunogenicity of monoclonal antimelanoma antibody-ricin A chain immunotoxin in rats.

Authors:  S Harkonen; J Stoudemire; R Mischak; L E Spitler; H Lopez; P Scannon
Journal:  Cancer Res       Date:  1987-03-01       Impact factor: 12.701

10.  The mechanism of action of ricin and related toxic lectins on eukaryotic ribosomes. The site and the characteristics of the modification in 28 S ribosomal RNA caused by the toxins.

Authors:  Y Endo; K Mitsui; M Motizuki; K Tsurugi
Journal:  J Biol Chem       Date:  1987-04-25       Impact factor: 5.157

View more
  6 in total

1.  A dominant linear B-cell epitope of ricin A-chain is the target of a neutralizing antibody response in Hodgkin's lymphoma patients treated with an anti-CD25 immunotoxin.

Authors:  D Castelletti; G Fracasso; S Righetti; G Tridente; R Schnell; A Engert; M Colombatti
Journal:  Clin Exp Immunol       Date:  2004-05       Impact factor: 4.330

2.  Pilot phase IB clinical trial of an alhydrogel-adsorbed recombinant ricin vaccine.

Authors:  Ellen S Vitetta; Joan E Smallshaw; John Schindler
Journal:  Clin Vaccine Immunol       Date:  2012-08-22

3.  Ribosome depurination is not sufficient for ricin-mediated cell death in Saccharomyces cerevisiae.

Authors:  Xiao-Ping Li; Marianne Baricevic; Hemalatha Saidasan; Nilgun E Tumer
Journal:  Infect Immun       Date:  2006-11-13       Impact factor: 3.441

4.  A monoclonal immunoglobulin G antibody directed against an immunodominant linear epitope on the ricin A chain confers systemic and mucosal immunity to ricin.

Authors:  Lori M Neal; Joanne O'Hara; Robert N Brey; Nicholas J Mantis
Journal:  Infect Immun       Date:  2009-10-26       Impact factor: 3.441

5.  A pilot clinical trial of a recombinant ricin vaccine in normal humans.

Authors:  Ellen S Vitetta; Joan E Smallshaw; Elaine Coleman; Hasan Jafri; Callie Foster; Robert Munford; John Schindler
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-03       Impact factor: 11.205

6.  Strong protection against ricin challenge induced by a novel modified ricin A-chain protein in mouse model.

Authors:  Tao Zhang; Hao Yang; Lin Kang; Shan Gao; Wenwen Xin; Wenwu Yao; Xiangjin Zhuang; Bin Ji; Jinglin Wang
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.